Britain and America have agreed to a key commercial pact that will preserve zero import taxes on British pharmaceutical shipments being sold in the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to boost funding on medicines through the public health system. This commitment secures that duties on these vital goods will be held at zero for a period of three years.
This deal is in response to recent statements to hike import taxes on patented pharmaceutical imports, with figures discussed as high as one hundred percent.
"This deal with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces long-overdue fairness to American-British pharmaceutical trade," an announcement noted.
Economic Importance
Pharmaceuticals are one of the UK's biggest export categories to the United States, which is clearly the biggest market for large British pharmaceutical firms.
Export figures reveal that in the year to the end of the third quarter, the UK shipped drugs worth £11.1bn to the US. This amount made up 17.4% of British export trade in that period.
"This guarantee safeguards work, increases investment and sets the stage for the UK to emerge as a worldwide center for medical research," a minister commented.
Key UK Commitments
The deal entails several key commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to double total health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must return to the NHS to prevent overspending will be capped at 15%. Last year, rebates exceeded twenty percent.
Industry Background
The deal takes place against a protracted dispute between the drug companies and the British authorities over medicine costs and NHS adoption.
This friction were heightened by claims that US customers were charged a premium for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the last ten years.
